Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Dostarlimab Plus Radiation in Locally Advanced MMR-D/MSI-H Endometrial Cancer
NCT04774419Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2021
- Primary completion
- Feb 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of dostarlimab in endometrial cancer (EC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Dose Limiting Toxicities at 8 weeks and Progression-Free Survival at 2 years. Started Apr 2021; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04774419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04774419.